Latest News
CervoMed Inc.
- CervoMed Inc. Estimates – NASDAQ:CRVO
- CervoMed stock rating reiterated at Buy by H.C. Wainwright on biomarker data
- CervoMed Updates Investors with New Regulatory Presentation
- CervoMed posts investor presentation disclosure; info added to website
- CervoMed reports encouraging biomarker data in Phase 2a trial
- CervoMed presents initial data from neflamapimod trial
- CervoMed reports biomarker decline in dementia trial By Investing.com
- CervoMed Presents Initial Results of Phase 2a Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Showing Positive Effects on a Key Neurodegeneration Biomarker in Late-Breaking Oral Session at ISFTD 2026
- CervoMed Shows Progress in Treating Rare Aphasia Condition
- A rare dementia can take away speech; no drug is approved for it. CervoMed saw a nerve-damage marker fall over 12 weeks.
- H.C. Wainwright reiterates Buy on CervoMed stock on new formulation
- Hopeful Week For Insiders Who Bought US$3.46m Of CervoMed Stock
Headlines from the last 30 days, linking to the original publishers. See all market news →